COMPANY PROFILE

NeuroKaire

Genetika+ is developing a tailored medical diagnostic instrument to help doctors cure depression. Genetika+ predicts the best pharmacological treatment for each patient, allowing faster treatment

Kearny, United StatesFounded 2017Biotech & Life Sciences

Valuation $25–50M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About NeuroKaire

Operator of a medical platform intended to personalize depression treatment for every individual. The company's platform leverages biological, medical, and genetic data and innovative technology to predict the optimal drug treatment, and helps pharma companies differentiate product offerings and de-risk clinical trials by identifying responders and stratifying patients, and transforming care for psychiatric and neurological diseases by combining stem-cell technology, genomics, and artificial intelligence for treatment optimization and effective drug development, enabling patients to get access to fast treatment with few side effects and low dosing. Keywords: Pharmaceuticals and Biotechnology, Depression Drugs, Depression Solutions, Depression Treatment, Mental Illness Therapy, Mental Illness Treatment, Mental Wellness.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Kearny, United States
Employees: 39
Open positions: None listed
Dealroom signal: 65.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology, Medical Devices, Health Platform
Sector: Biotech & Life Sciences, Biotechnology
Technology: Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Deep Learning, Computer Vision
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Dec 2024	$10M	$40M	GreyBird Ventures · JumpSpeed Ventures · Meron Capital	↗
GRANT✓Other financing	Mar 2022	$2.5M	—	European Innovation Council	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

NeuroKaire website traffic

Latest recorded traffic for NeuroKaire is 3K monthly website visits, down 52.4% over the last three months. NeuroKaire's team declined 11.4% over the past year.

Latest monthly visits3K 3-month web change-52.4% 1-year team growth-11.4%

Monthly website visitsJun 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ILiLoFAI and photonics platform for personalized drug discovery.	London, United Kingdom	Operational	40	$13M	$22M
PHPharmaceleraQuantum mechanics and AI powered drug discovery platform	Barcelona, Spain	Operational
THTHERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care	Paris, France	Operational
IRIris.aiAn AI based platform for R&D departments to make research documentation actionable	Bærum, Norway	Operational
PEPepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets	Jerusalem, Israel	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
ATArctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics	Reykjavík, Iceland	Operational
MIMindPeakMindPeak automates visual diagnosis, making microscopical analysis more accessible to support in accurate cancer diagnoses	Hamburg, Germany	Operational